IN2014CN02671A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02671A
IN2014CN02671A IN2671CHN2014A IN2014CN02671A IN 2014CN02671 A IN2014CN02671 A IN 2014CN02671A IN 2671CHN2014 A IN2671CHN2014 A IN 2671CHN2014A IN 2014CN02671 A IN2014CN02671 A IN 2014CN02671A
Authority
IN
India
Prior art keywords
formula
compound
administering
treating
combination
Prior art date
Application number
Other languages
English (en)
Inventor
Arthur Decillis
Soto Rodrigo Ruiz
Gary Thomas Emmons
Joanne Lager
Original Assignee
Exelixis Inc
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Sanofi Sa filed Critical Exelixis Inc
Publication of IN2014CN02671A publication Critical patent/IN2014CN02671A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2671CHN2014 2011-09-14 2015-05-22 IN2014CN02671A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161534836P 2011-09-14 2011-09-14
US201161543529P 2011-10-05 2011-10-05
US201161562670P 2011-11-22 2011-11-22
PCT/US2012/055387 WO2013040337A1 (en) 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
IN2014CN02671A true IN2014CN02671A (cg-RX-API-DMAC7.html) 2015-07-03

Family

ID=46940622

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2671CHN2014 IN2014CN02671A (cg-RX-API-DMAC7.html) 2011-09-14 2015-05-22

Country Status (10)

Country Link
EP (1) EP2755654A1 (cg-RX-API-DMAC7.html)
KR (1) KR20140077911A (cg-RX-API-DMAC7.html)
AU (1) AU2012308414A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014005858A2 (cg-RX-API-DMAC7.html)
CA (1) CA2848724A1 (cg-RX-API-DMAC7.html)
IL (1) IL231448A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02671A (cg-RX-API-DMAC7.html)
TW (1) TW201325592A (cg-RX-API-DMAC7.html)
UY (1) UY34339A (cg-RX-API-DMAC7.html)
WO (1) WO2013040337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754565B (zh) * 2021-11-09 2022-02-22 南京威凯尔生物医药科技有限公司 一种连续流微反应器中制备沙库巴曲中间体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
HRP20130902T1 (hr) 2005-10-07 2013-11-08 Exelixis Inc. PIRIDOPIRIMIDINONSKI INHIBITORI PI3Kalfa
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
HRP20140975T1 (hr) * 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
UA98141C2 (ru) * 2007-04-11 2012-04-25 Экселиксис, Инк. Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
WO2010146391A1 (en) * 2009-06-15 2010-12-23 Generics [Uk] Limited Regioselective synthesis of letrozole
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
WO2013040337A9 (en) 2014-04-03
EP2755654A1 (en) 2014-07-23
WO2013040337A1 (en) 2013-03-21
CA2848724A1 (en) 2013-03-21
TW201325592A (zh) 2013-07-01
AU2012308414A1 (en) 2014-05-01
IL231448A0 (en) 2014-04-30
BR112014005858A2 (pt) 2017-06-13
KR20140077911A (ko) 2014-06-24
UY34339A (es) 2013-04-30

Similar Documents

Publication Publication Date Title
PH12015501058A1 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
PH12012501719A1 (en) Compounds for immunoproteasome inhibition
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
EA201400178A1 (ru) Лечение рака молочной железы
EA201591145A1 (ru) Ингибиторы гистондеметилазы
MX368286B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2014005458A (es) Inhibidor doble de met y del factor de crecimiento endotelial vascular (vegf) para el tratamiento del cáncer.
PH12014502047B1 (en) Treatment of cancer with tor kinase inhibitors
GEP201706612B (en) Methods for the treatment of breast cancer
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
PH12015501038A1 (en) Inhibitors of iap
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
MX371020B (es) Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico.
PH12012501945A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MX2013012486A (es) Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor).
EA201491506A1 (ru) Новое применение кабазитаксела в педиатрии
NZ709094A (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer